The Pharmaceutical Market: Denmark

SUMMARY

The Danish pharmaceutical market is small but very wealthy. This report is ideal for executives wanting to understand the key drivers in the pharmaceutical market and have access to a wealth of statistical data, including five-year market projections. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.

Denmark is a global leader in the manufacture of insulin and as a consequence has retained a healthy balance of payments surplus for the past five years; in 2005, the surplus was in excess of US$606.4 million.

Prior to April 2005, there was a price freeze on pharmaceuticals and reimbursement levels were based upon reference prices in other northern European countries. Since then, reimbursement levels for each class have been based on the cheapest generic drug. This has led LiF, the Danish pharmaceutical trade association, to query how long the price freeze can be maintained, especially as there is a constant downward pressure on prices.

There is strong domestic production although many producers focus on Denmark's export market, therefore many pharmaceutical imports are in retail-ready packages. Parallel imported products constitute 12.1% of pharmaceuticals consumed in Denmark, with 34.9% of respiratory drugs being parallel imported.

The pharmaceutical market in Denmark is estimated to be valued at equal to US$686 per capita in 2007. Although 73.1% of the market originates in the primary care sector, pharmaceutical sales in the hospital sector averaged 14.7% growth per year in the period 2000-2005. In the primary care sector, pharmaceutical sales grew by 4.9% in a similar period.

TABLE OF CONTENTS

DENMARK BACKGROUND DATA

• GEOGRAPHY
• POLITICAL OVERVIEW
• ECONOMIC OVERVIEW
  • Gross Domestic Product, 2007-2012
• POPULATION
  • Population Trends, 2005-2007
  • Population by Region & Gender, 2006
  • Population by Age & Gender, 2006
• DEMOGRAPHIC INDICATORS
  • Demographic Indicators, 2000-2006
• MORTALITY
  • Causes of Death, 2005
• MORBIDITY
• Cancer Incidence
  • Most Common Types of Cancer Among Male (New Cases), 2003
  • Most Common Types of Cancer Among Female (New Cases), 2003
• HIV / AIDS
  • Diagnosed Cases of AIDS, 1999-2005
  • HIV Cases by mode of transmission, 2000-2005

CHARTS

• Map of Denmark
• Population by Age, 2006 (%)
• Causes of Death, 2005 (%)

DENMARK HEALTHCARE SYSTEM

• ORGANISATION & ADMINISTRATION
• HEALTH EXPENDITURE
• HOSPITAL SERVICES
• Hospital Resources
  • Hospitals by Type, 2004
  • Hospitals by Region, 2004
  • Hospital Beds by Region, 1993-2004
  • Hospital Beds by Specialty, 2004
  • Hospital Beds by Specialty, 1996-2000
  • Hospital activity by Year, 2000-2005
  • Hospital Activity Summary by ICD-10 Classification and Year, 2002-2005
  • Hospital Patients, 2003-2005
  • Hospital Admissions, 2003-2005
  • Average length of Stay, 2002-2003
• Private Hospitals
• AMBULATORY CARE
  • Outpatient Activity by Region, 2002-2004
  • Outpatient Activity by Specialty, 2002-2004
• MEDICAL PERSONNEL
  • Persons Employed in the Hospital Sector, 1995-2004
  • Primary Sector Medical Personnel, 1990-1999

CHARTS

• Central Government Expenditure on Health, 2001-2005

DENMARK ACCESSING THE PHARMACEUTICAL MARKET

• INTRODUCTION
• REGULATORY ENVIRONMENT
  • Centralised Procedure
  • The EMEA
  • Mutual Recognition Procedure
• Pharmaceutical Registration
  • Clinical Trials
• Advertising
• Patent Protection & Intellectual Property Rights
  • Supplementary Protection Certificates
• Pricing and Reimbursement
  • Pricing
  • Price Index
  • The Price List of Proprietary Medicinal Products
  • DKMAnet Prices and Packages
  • Generic substitution
  • Reimbursement
  • Relationship Between Annual Consumption and Pharmaceutical Reimbursement, 2007
• DISTRIBUTION CHANNELS
  • Pharmacies, 1990 - 2004
• Distributors
  • Amgros
  • Dupharma
  • Missionpharma
• Parallel Imports
• DOMESTIC PRODUCTION
  • Domestic Pharmaceutical Manufacturing Turnover, 2001-2006
• Trade Associations
• Domestic Producers
  • ALK-Abelló
  • Genmab A/S
  • Hexal A/S
  • Leo Pharma
  • Lundbeck A/S
  • Novo Nordisk
  • PharmaDanica
  • Pharmexa
• Research & Development
  • Pharmaceutical Research & Development Expenditure by Lif's Member Companies, 1990-2000 (DKr Million)
• DIRECTORY
• Government Organisations
• Trade Associations